XENE (Xenon Pharmaceuticals) EBITDA Margin %: 0.00% (As of Mar. 2026)


XENE Xenon Pharmaceuticals Inc XENE
25 GF Score
Price $59.74
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals EBITDA Margin %?

Xenon Pharmaceuticals XENE +5.21% 25 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Xenon Pharmaceuticals ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xenon Pharmaceuticals's EBITDA for the three months ended in Mar. 2026 was $-111.74 Mil. Xenon Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Xenon Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Xenon Pharmaceuticals  (NAS:XENE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Xenon Pharmaceuticals EBITDA Margin % Related Terms

Xenon Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals EBITDA Margin % Chart

Xenon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -423.53 -1,354.02 0.00 0.00 -4,940.36

Xenon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -961.05 0.00 0.00 0.00 0.00

XENE vs CRSP, CGON, DNTH: EBITDA Margin % Comparison

For the Biotechnology subindustry, Xenon Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's EBITDA Margin % falls into.


XENE
25GF Score
Xenon Pharmaceuticals Inc XENE
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Xenon Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-370.527/7.5
=-4,940.36 %

Xenon Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-111.741/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Xenon Pharmaceuticals (XENE) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xenon Pharmaceuticals and its competitors. According to the industry distribution chart, Xenon Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry.
Is Xenon Pharmaceuticals' EBITDA Margin % too high?
Xenon Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Xenon Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' EBITDA Margin % compare to CRSP and CGON?
According to the Biotechnology industry distribution chart, Xenon Pharmaceuticals ranks #999999 out of 944 companies for EBITDA Margin %. This places Xenon Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xenon Pharmaceuticals and its competitors. Xenon Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xenon Pharmaceuticals Business Description

Other Exchanges XP0:Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score

Get the complete analysis for XENE

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.74
Price